Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rosuvastatin Oral Tablet Clear all
Recruiting Phase 1 Interventional

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

NCT07372625
View directory record Official record
Conditions
TP53 Y220C Mutation, Advanced Solid Tumors
Interventions
metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

NCT04008186
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442
View directory record Official record
Conditions
Healthy Participants
Interventions
Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 23, 2026, 6:57 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

NCT07534592
View directory record Official record
Conditions
Healthy Participants
Interventions
Elecoglipron, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

NCT06092931
View directory record Official record
Conditions
Healthy Participants
Interventions
DC-806, Midazolam, Repaglinide, Digoxin, Rosuvastatin
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

NCT01751074
View directory record Official record
Conditions
Atherosclerosis
Interventions
Rosuvastatin 10 mg, Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

NCT07316608
View directory record Official record
Conditions
Healthy Participants
Interventions
Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2, Laroprovstat Dose X STP, Rosuvastatin Dose 1 STP, Rosuvastatin Dose 2 STP
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
ECC5004, Midazolam, Rosuvastatin, Digoxin, Atorvastatin
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

NCT02371603
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 23, 2026, 6:57 PM EDT
Recruiting Phase 3 Interventional

PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

NCT07232069
View directory record Official record
Conditions
Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions
Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 60 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study With Rosuvastatin

NCT02101125
View directory record Official record
Conditions
Immunosuppression For Disease
Interventions
BMS-986020, Rosuvastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 23, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

NCT04764851
View directory record Official record
Conditions
Drug-Interactions
Interventions
ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 23, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

NCT03113994
View directory record Official record
Conditions
Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome
Interventions
Rosuvastatin Calcium, Placebo Oral Tablet, Coenzyme Q10, Calcium Carbonate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Dr. B. Catharine. Craven
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

NCT01725230
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib, Rosuvastatin, Simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

NCT01489943
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786 500 mg, Midazolam 3 mg, Pioglitazone 15 mg, Omeprazole 40 mg, Rosuvastatin 10 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

NCT06948747
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Rosuvastatin, Erythromycin, Atorvastatin, Simvastatin, Repaglinide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

NCT05334108
View directory record Official record
Conditions
Drug Interaction
Interventions
Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate, Cohort 3 Probe Substrate Cocktail
Drug · Combination Product
Lead sponsor
Emalex Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

NCT06567327
View directory record Official record
Conditions
Obesity
Interventions
Danuglipron, Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

NCT05384262
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD0780, Placebo, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

NCT07222098
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Metformin, Calderasib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

NCT04252300
View directory record Official record
Conditions
Drug Interactions
Interventions
Rosuvastatin, Rosuvastatin + BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 23, 2026, 6:57 PM EDT
Withdrawn Phase 1 Interventional

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

NCT05828303
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
TPX-0005, Metformin Hydrochloride, Digoxin, Rosuvastatin Calcium
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 23, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers

NCT03699774
View directory record Official record
Conditions
Drug Pharmacokinetics in Healthy Volunteers
Interventions
DS-8500a, Rosuvastatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 23, 2026, 6:57 PM EDT